Share General Information
Deucravacitinib is a Tyrosine Kinase 2 Inhibitor. The mechanism of action of deucravacitinib is as a Tyrosine Kinase 2 Inhibitor. Deucravacitinib was first approved by the FDA in September 2022 to treat moderate-to-severe plaque psoriasis.
About the API
-
Japan DMF
-
Korea DMF
-
US DMF
The information detailed herein, including that with regard to active pharmaceutical ingredients , their use in treatments and possible mechanism(s) of action, was all obtained from public sources.
For more information on our services and products – including product suitability, intended uses and current availability – please contact Teva api Customer Service. CAS Registry Number is a Registered Trademark of the American Chemical Society. This webpage and any reference to the above product is to be read within the meaning and terms of the Legal Notes.
